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Metabolic syndrome (MS) is a cluster of metabolic disorders that collectively increase the
risk of cardiovascular disease. Nitric oxide (NO) plays a crucial role in the pathogeneses
of MS components and is involved in different mitochondrial signaling pathways that
control respiration and apoptosis. The present review summarizes the recent information
regarding the interrelations of mitochondria and NO in MS. Changes in the activities of
different NO synthase isoforms lead to the formation of metabolic disorders and therefore
are highlighted here. Reduced endothelial NOS activity and NO bioavailability, as the main
factors underlying the endothelial dysfunction that occurs in MS, are discussed in this
review in relation to mitochondrial dysfunction. We also focus on potential therapeutic
strategies involving NO signaling pathways that can be used to treat patients with
metabolic disorders associated with mitochondrial dysfunction. The article may help
researchers develop new approaches for the diagnosis, prevention and treatment of MS.
Keywords: metabolic syndrome, mitochondrial dysfunction, nitric oxide synthase, nitric oxide, nitric oxide
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INTRODUCTION
Metabolic syndrome (MS) is a global epidemic, and differ-
ent environmental, genetic and pathophysiological factors are
involved in its development. Mitochondria play central roles
in energy metabolism, signaling and apoptosis and its alter-
ations may contribute to the development of metabolic disorders
(Peinado et al., 2014). It has been recently found that mito-
chondrial biogenesis and function are enhanced by nitric oxide
(NO), which is a key signaling molecule in vascular homeosta-
sis. This finding indicates that changes in the production of NO
bioavailability and MS may be associated with the mitochon-
dria. However, the link between NO signaling components and
mitochondria in MS in different tissues is still not clear.
Today, mitochondria remains an attractive target for the pre-
vention and therapy of MS and its complications (Sorriento et al.,
2014). Understanding the mechanisms that lead to decreased
mitochondrial activity in insulin-sensitive tissues is important for
developing therapies to reverse insulin resistance. A deeper under-
standing of the role of NO pathway components in this process
opens up new opportunities for applied research in this area.
METABOLIC SYNDROME AND MITOCHONDRIAL
DYSFUNCTION
Mitochondrial dysfunction is closely associated with obesity,
metabolic syndrome and type 2 diabetes mellitus (T2DM)
(Lowell and Shulman, 2005; Agrawal and Prakash, 2014).
Changes in the mitochondrial membrane potential, a reduc-
tion in the ATP level, the inhibition of mitochondrial oxy-
gen consumption and reduced mitochondrial biogenesis (Ren
et al., 2010) are some of the characteristics of mitochondrial
dysfunction (Pieczenik and Neustadt, 2007). The underlying
mechanism of mitochondrial dysfunction is very complex, which
includes genetic factors from both nuclear and mitochondrial
genome and numerous environmental factors (Lee et al., 2010).
In addition to these factors, excessive formation of reactive oxygen
species (ROS) in obesity and T2DM (Chattopadhyay et al., 2015)
contributes to mitochondrial dysfunction, while at physiological
levels ROS participate in intracellular signaling and regulation as
“redox messengers.” Particularly, superoxide anion generated by
the mitochondria, particularly by complexes I and III of the elec-
tron transport chain (ETC), is the precursor of most ROS and a
mediator in oxidative chain reactions. Dismutation of superox-
ide produces hydrogen peroxide, which in turn may be partially
reduced to hydroxyl radical causing more damage to various
mitochondrial and cellular components (Turrens, 2003). Free
radical damage to mitochondria may lead to decreased affinity
of mitochondrial proteins for substrates or coenzymes (Liu et al.,
2002).
The centerpiece of the pathophysiologic mechanism of MS is
insulin resistance. The interplay between mitochondrial dysfunc-
tion and insulin resistance was first discovered in 1963 (Laguens
and Bianchi, 1963). Kitt Falk Petersen et al. demonstrated that
insulin resistance, which frequently occurs in elderly individuals,
is characterized by a decrease in mitochondrial ATP produc-
tion, a reduction in mitochondrial RNA, decreased activity of
oxidative phosphorylation complexes (Petersen et al., 2003). It
is still unclear whether mitochondrial dysfunction results from
or causes insulin resistance (Martin and McGee, 2014). One of
the key pathophysiological factors underlying the formation of
insulin resistance may be the dysregulation of energy metabolism
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in insulin-sensitive tissues such as skeletal muscle, liver, and adi-
pose (Litvinova et al., 2014). Particularly, in skeletal muscle,
decreased mitochondrial respiration capacity, reduced ATP pro-
duction, and increased ROS levels lead to reduced fatty acid
oxidation and increased cytosolic free fatty acid levels, resulting in
insulin resistance and T2DM (Pagel-Langenickel et al., 2010). Tg
(sm/p22phox) mice, which produce increased vascular ROS, dis-
play impaired spontaneous activity and increased mitochondrial
ROS production and mitochondrial dysfunction in their skeletal
muscle (Youn et al., 2014). As regards liver, there are findings that
strongly support that non-alcoholic fatty liver disease can be con-
sidered as the hepatic representation of MS (Paschos and Paletas,
2009). Insulin resistance is a key pathogenic factor in both patho-
logic states. It has been shown that patients with non-alcoholic
fatty liver disease had decreased activities of ETC complexes in
liver (Pérez-Carreras et al., 2003). Recent findings suggests that
reduced SIRT3 activity in fatty liver may result in hyperacetyla-
tion of mitochondrial proteins that contributes to mitochondrial
dysfunction (Kendrick et al., 2011). Nitrosative stress in non-
alcoholic fatty liver disease also contributes to the development
of mitochondrial dysfunction that is mediated by the oxidative
modifications of mitochondrial DNA (mtDNA), lipids and pro-
teins (Song et al., 2013). Moreover, high-fat diet-induced mtDNA
damage correlates with increased oxidative stress in skeletal mus-
cle and liver, which is associated with the induction of markers of
endoplasmic reticulum stress, protein degradation and apoptosis
(Yuzefovych et al., 2013). In adipose tissue, mitochondria provide
key intermediates for the synthesis of triglycerides and are criti-
cal for lipogenesis. Adipose mitochondria are also important for
lipolysis through the oxidation of fatty acids, which constitutes
an important source of ATP to supply cells with energy (Serra
et al., 2013).The study of M. Rossmeisl et al. demonstrated that
uncoupling of oxidative phosphorylation depresses fatty acid syn-
thesis in white fat (Rossmeisl et al., 2000). The authors show
that reduction of adiposity via mitochondrial uncoupling in
white fat not only reflects increased energy expenditure, but also
decreased in situ lipogenesis. Therefore, various studies suggest
that modulation of mitochondrial function (including oxidative
phosphorylation, ATP synthesis and ROS generation) in above-
mentioned tissues may in turn may affect the development of
insulin resistance and obesity.
Mitochondrial dysfunction and insulin resistance promote
chronic inflammation and the formation of atherosclerotic
lesions, and the activation of the inflammatory Toll-like recep-
tor 2/nuclear factor-κB signaling pathway in monocytes is a
central mechanism leading to a vicious cycle between chronic
inflammation and mitochondrial ROS production (Hulsmans
et al., 2012). Tumor necrosis factor (TNF)-α is a key proinflam-
matory mediator that plays an important role in the chronic
inflammation of adipose tissue in obese subjects (Hotamisligil
et al., 1993). It has been concluded that TNF-α also induces
mitochondrial dysfunction by reducing complex III activity in
the ETC, increasing ROS production, and causing damage to
mtDNA in cardiac myocytes (Suematsu et al., 2003). It has been
demonstrated in mice with adipocytes deficient in mitochondrial
transcription factor A that isolated mitochondrial dysfunction
in adipose tissue can cause lipodystrophy and lead to MS and
chronic inflammation (Vernochet et al., 2014). Thus, mitochon-
drial alterations that occur during insulin resistance trigger a
cascade of pathological processes in different tissues and form
a vicious cycle between chronic inflammation and mitochon-
drial oxidative stress that eventually contributes to cardiovascular
pathologies and T2DM.
MITOCHONDRIAL DNA AS A MOLECULAR MARKER OF
METABOLIC SYNDROME
MtDNA is a 16569-bp, circular, double-stranded molecule that
harbors 37 genes involved in the energy production that takes
place in the ETC. This gene set includes 13 structural genes that
code for subunits of oxidative phosphorylation complexes as well
as genes encoding 22 tRNAs and 2 rRNAs that are involved in
the protein synthesis that occurs directly within mitochondria
(Smits et al., 2010). According to current estimates, the human
genome incorporates approximately 2500 mitochondrial protein-
encoding genes; however, only fewer than 1000 of these proteins
have been identified in isolated mitochondria (Jiang and Wang,
2012).
It is now established that mtDNA polymorphisms may be risk
factors for T2DM and other metabolic pathologies (Nishigaki
et al., 2011). The substitution 16189T>C in the D-loop region
of mtDNA has been shown to be associated with insulin resis-
tance, obesity and T2DM in both European (Poulton et al., 2002)
and Asian (Kim et al., 2002) populations. Analysis of mtDNA
has also shown that haplogroup N9A may be a protective fac-
tor against MS in Japanese women (Tanaka et al., 2007) and
against T2DM in Japanese and Korean individuals (Fuku et al.,
2007). Furthermore, mutations in mtDNA have been indepen-
dently associated with multiple phenotypes of MS. The T4291C
mutation inmtDNAhas been shown to be associated withMS in a
large Caucasian family, and a commonmtDNA variant, T16189C,
has been shown to be associated with a lower body mass index at
birth, insulin resistance, dilated cardiomyopathy and an increased
susceptibility to MS in a Chinese population (Palmieri et al.,
2011). Moreover, the mtDNA mutation A8890G has been found
in a patient with juvenile-onset MS (Ye et al., 2013).
Changes in the amount of mtDNA may be a consequence of
genetic defects (Rötig and Poulton, 2009) and hormonal imbal-
ances in non-hereditary diseases (Liu et al., 2003). Our results
showing a reduced number of mtDNA copies in peripheral blood
and samples of adipose tissue obtained from different locations
from patients with MS (Mozhey et al., 2014) are consistent with
the results of previous studies. It has been previously shown that
decreased mtDNA content in peripheral blood occurs before the
onset of T2DM (Lee et al., 1998). The administration of piogli-
tazone, which is a mainstay drug for the treatment of T2DM,
leads to an increase in the number of mtDNA copies in sub-
cutaneous adipocytes in vitro (Bogacka et al., 2005). As previ-
ously mentioned, mtDNA levels may vary in different organs.
However, experiments performed in rats have shown that changes
in mtDNA copy number in peripheral blood leukocytes reflect
similar processes in muscle tissue and hepatocytes. Thus, we can
assume that the level of mtDNA in human peripheral blood
cells is an indicator of various metabolic disorders. Moreover,
the quantitative estimation of mtDNA in various biological
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samples might become a tool for the prognosis and estimation
of treatment efficiency of MS.
INTERCONNECTIONS BETWEEN MITOCHONDRIA AND
NITRIC OXIDE PRODUCTION IN DIFFERENT TISSUES
NO is a relatively stable gas that belongs to a family of gas
transmitters with similar inherent intracellular effects. NO is a
regulator of many physiological processes. It is synthesized by
vascular endothelial cells, is responsible for vasodilatation and is
involved in various processes in the nervous, reproductive and
immune systems. NO prevents platelet aggregation and the adhe-
sion of neutrophils to the endothelium, and it has cytostatic and
cytotoxic properties (Ufnal and Z˙era, 2010). In addition to its par-
ticipation in the regulation of vascular smooth muscle tone, NO
directly affects mitochondrial respiration (Lee, 2000). Its inhibi-
tion of ETC enzymes may also be one of the causes of the decrease
in oxygen consumption by cardiomyocytes. NO plays important
roles in the development ofMS components, such as insulin resis-
tance, endothelial dysfunction, hypertriglyceridemia and chronic
adipose tissue inflammation.
NO is formed from L-arginine, when in the presence of
oxygen, by isoenzymes of nitric oxide synthases (NOS), which
depend on the cell type. Endothelial NOS (eNOS) and neuronal
NOS (nNOS) are constantly active and produce small amounts
of NO in response to stimuli that induce an increase in the
intracellular Ca2+ concentration (Förstermann and Sessa, 2012).
Inducible NOS (iNOS), which is a calcium-independent form of
NOS, is localized to macrophages, neutrophils, and micro- and
astroglial cells and is expressed under the influence of factors
such as cytokines and bacterial lipopolysaccharide (Yang et al.,
2014). The mitochondrial production of NO is catalyzed by mito-
chondrial NOS (mtNOS), which has been identified as the alpha
isoform of nNOS that is acylated at a Thr or Ser residue and
phosphorylated at the C-terminus.
Impaired NOS activity is closely associated with insulin resis-
tance (Kashyap et al., 2005). The work of Nisoli’s group has firmly
established the function of NO generated by eNOS and nNOS as
an upstream regulator of mitochondrial biogenesis (Nisoli et al.,
2003). Experiments with homozygous eNOS knockout mice have
definitively proven the relationship between NO and insulin sen-
sitivity because these mice show increased blood pressure and
insulin resistance (Shankar et al., 2000).
Endothelial dysfunction, which is defined by a decrease in
flow-mediated vasodilatation and vascular insulin resistance, rep-
resents an established vascular abnormality in diabetic patients
(Montagnani et al., 2001). The possible underlying mechanisms
include reductions in the levels of eNOS mRNA expression
and protein production (Huang, 2009). In particular, Alvarado-
Vásquez et al. have shown that human umbilical vein endothelial
cells isolated from healthy newborns with a strong family his-
tory of T2DM exhibit abnormal intracellular synthesis of NO
and impaired expression of the eNOS, GLUT1 and p53 genes,
which are all associated with NO synthesis (Alvarado-Vásquez
et al., 2007). However, studies in animal models and in humans
have assumed that T2DM and atherosclerosis are not necessar-
ily associated with reductions in total eNOS (Felaco et al., 2001).
Several mechanisms leading to endothelial dysfunction, such as a
lack of enzymatic cofactors for eNOS (Mangge et al., 2014), the
inactivation of NO by the reaction of superoxide (O2-) result-
ing in peroxynitrite anion (OONO-) formation (Pacher et al.,
2007), the influence of superoxide NADPH oxidase (Griendling
et al., 2000) and “uncoupled” eNOS, have been demonstrated
(Figure 1). Peroxynitrite, in turn, has been shown to uncouple
endothelial nitric oxide synthase (eNOS), thereby converting an
antiatherosclerotic NO-producing enzyme into an enzyme that
may accelerate the atherosclerotic process by producing superox-
ide (Schulz et al., 2008). It should be noted that these mechanisms
are not mutually exclusive and can occur simultaneously. The
studies of Youn et al. have demonstrated that the p47phox and
NOXO1-dependent activation of NOX1, but not of NOX2, NOX4
or mitochondria, mediates the diabetic uncoupling of eNOS
(Youn et al., 2012). Interestingly, NOX1-null mice are protected
from diabetic endothelial dysfunction, and mice lacking com-
ponents of NOX2 are protected against hypertension and show
reduced atherosclerotic lesion formation when crossed with the
apoE-/- background (Judkins et al., 2010).
ROS derived from mitochondria induce the infiltration and
activation of inflammatory cells and increase the apoptosis of
endothelial and vascular smooth muscle cells (Hulsmans et al.,
2012). Excessive formation of peroxynitrite, which is a reac-
tive nitrogen species, has been demonstrated to accelerate the
atherosclerotic process by causing direct structural damage and
further ROS production (Münzel et al., 2010). Peroxynitrite
also damages DNA and thus triggers the activation of DNA
repair systems. A DNA nick-sensor enzyme, poly(ADP-ribose)
polymerase-1 (PARP-1), also becomes activated upon sensing
DNA breakages. Activated PARP-1 cleaves NAD(+) into nicoti-
namide and ADP-ribose and polymerizes the latter onto nuclear
acceptor proteins. The peroxynitrite-induced overactivation of
PARP leads to the consumption of NAD(+) and consequently,
ATP, culminating in cell dysfunction, apoptosis or necrosis (Virág
et al., 2003). This mechanism of cell death has been implicated in
themolecular aspects of T2DM-associated cardiovascular disease.
Recent data have indicated the possibility of a significant
role for interrelations between PARP-1 and iNOS in human
atherosclerotic lesions. The induction of PARP-1 within the
nuclei of lesional smooth muscle cells has been correlated with
alterations in mitochondrial morphology (Perrotta et al., 2011).
Therefore, it should be concluded that plaque formation is one
of the consequences of the PARP-1-mediated mechanism that is
involved in changes in mitochondrial morphology.
It has been reported that deletion of eNOS or the phar-
macological inhibition of NOS impacts baseline and exercise-
stimulated vascular mitochondrial biogenesis and dynamics
(Miller et al., 2013). In particular, in cultured human aortic
endothelial cells, a similar loss of mitochondrial networks and
increased expression of mitochondrial fission 1 protein (Fis1) and
dynamin-related protein-1 (Drp1), which are proteins required
for mitochondrial fission, have been demonstrated. The silencing
of Fis1 or Drp1 expression by siRNA reduces high glucose-
induced alterations in mitochondrial networks, ROS production,
eNOS activation, and cGMP production (Shenouda et al., 2011).
The increased expression of Fis1 and Drp1 and decreased expres-
sion of fusion proteins (Opa1, Mfn1, and Mfn2) in addition to
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FIGURE 1 | Interrelation between nitric oxide and mitochondria in the
pathophysiology of metabolic syndrome (a, in the vascular wall; b, in an
adipocyte; c, in a hepatocyte). a: Insulin resistance contributes to decreased
activities of signaling molecules, which leads to decreased eNOS activity.
Superoxide generated in mitochondria can modestly, and peroxynitrite can
strongly, oxidize BH4–BH2, leading to uncoupling of eNOS, increased
production of ROS and endothelial dysfunction. Moreover, mtNOS becomes
“uncoupled”; it switches from a NO-generating enzyme to a
superoxide-producing enzyme. Increased production of peroxynitrite and
superoxide anions generated from uncoupled mtNOS and eNOS damage
mitochondrial ETC complexes, leading tomitochondrial dysfunction. eNOS then
generates superoxide rather than NO, which contributes to vascular oxidative
stress and further reduces NO bioavailability. Excessive mtNOS-derived NO
can produce reactive nitrogen species, such as peroxynitrite, which may cause
tyrosine nitration of mitochondrial components and may play a key role in
apoptosis. Under the conditions of oxidative stress, the enhanced activity of
iNOS, with less contribution of nNOS, in vascular smooth muscle cells induces
the development of chronic metabolic inflammation.
decreases in cAMP response element binding protein and PGC-
1α have also been observed in aortic tissues of eNOS-null rodents
(Miller et al., 2013). These data suggest that NOS is a biologically
important modulator of basal vascular mitochondrial function
and structure.
Enhanced iNOS gene expression and production in different
tissues, especially in insulin-sensitive tissues, leads to peroxyni-
trite formation, causing nitrosative and oxidative stresses. Recent
studies have shown the involvement of TNF-α-induced iNOS
in the expression of mitochondrial protein uncoupling protein-
2 (UCP-2) in adipocytes (Merial et al., 2000) as well as in NO
bioavailability in adipose tissue (Tian et al., 2012) (Figure 2). It
should be concluded that plaque formation is one of the conse-
quences of the PARP-1-mediated mechanism involved in changes
in mitochondrial morphology.
Since it was first reported in 1995, the existence of mtNOS has
been controversial (Giulivi et al., 1998). It has also been reported
that the addition of calcium to mitochondria isolated from hepa-
tocytes stimulates mtNOS, causing peroxynitrite production and
cytochrome c release, which are associated with the peroxidation
of mitochondrial lipids (Ghafourifar et al., 1999) (Figure 3).
Mitochondrial lipid peroxidation may be an important event
in mitochondria-mediated apoptosis (Nomura et al., 1999), but
there is no direct evidence that lipid peroxidation mediates NO-
induced apoptosis. The NO-synthesizing capacity of mtNOS
is higher than all of the cytoplasmic NOS isoforms combined
(Brookes, 2004). The discovery of Ca-dependent mtNOS was
an outstanding achievement that elucidated late aging-related
metabolic alterations that had taken years to become apparent
(Ghafourifar and Cadenas, 2005). The participation of mtNOS
appears to be of primary importance but remains to be fully
elucidated.
POTENTIAL THERAPEUTIC TARGETS AFFECTING
MITOCHONDRIAL DYSFUNCTION AND THE NITRIC OXIDE
PATHWAY IN METABOLIC SYNDROME
Different research groups have studied various ways to regulate
NO signaling pathways to modulate mitochondrial dysfunction.
NO signaling in mitochondria underlies many of the metabolic
effects of NO, and at low physiologic levels, links the cellular
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FIGURE 2 | Interrelation between nitric oxide and mitochondria in
adipose tissue in metabolic syndrome. The proinflammatory
microenvironment of adipose tissue induces the iNOS activity in MS
that increases peroxynitrite synthesis, thus contributing to oxidative
stress and chronic inflammation. Under the influence of these
conditions the reduced expression of the mitochondrial protein UCP-2
promotes the formation of MS components through decreased NO
bioavailability and increased ROS generation. Reduction in the
expression of mitochondrial transcription factor A also contributes to
the development of MS components.
energy demand with the mitochondrial energy supply, while
beneficially affecting mitochondrial oxidative stress and calcium
handling (Levine et al., 2012).
Increasing the mitochondrial concentrations of antioxidant
drugs by the selective targeting of mitochondria should repre-
sent a practical approach for the treatment of a wide range of
human diseases. The stimulation of cultured cardiac myocytes
with TNF-α or angiotensin II increases ROS generation and
myocyte hypertrophy, and treatment with antioxidants inhibits
both of these effects (Nakamura et al., 1998). Mitochondria-
targeted antioxidants have been developed as pharmaceuticals
and have been shown to be safe and effective in phase II clinical
trials. Despite these facts and a number of pre-clinical and clini-
cal lines of evidence, the results of studies assessing the effects of
classical antioxidants, such as vitamin C, vitamin E, or folic acid
in combination with vitamin E, have been disappointing (Münzel
et al., 2010).
Medications used to treat T2DM focus on reducing blood
glucose levels. Oral antihyperglycemic medications are used in
T2DM to increase organ sensitivity, increase insulin secretion,
or decrease glucose absorption during digestion. Insulin and
metformin represent the first-line treatments for T2DM (Blake
and Trounce, 2014), and their effects on mitochondrial func-
tion may contribute to the mechanism underlying dysfunction in
T2DM. Different hypoglycemic agents, and exercise may reduce
oxidative stress in diabetic patients through reducing NOX activ-
ity or improving mitochondrial function, which may prevent
or postpone the development of cardiovascular complications
(Shen, 2010). Moreover, substances such as statins, angiotensin-
converting enzyme inhibitors, or AT1-receptor blockers, which
possess indirect antioxidant properties mediated by the stim-
ulation of NO production and by the simultaneous inhibition
of superoxide production, have been shown to improve vascu-
lar function in pre-clinical and clinical studies and to reduce
the incidence of cardiovascular events in patients with cardio-
vascular disease (Münzel et al., 2010). These drugs and the
NO-releasing β-blocker nebivolol have been shown to pos-
sess combined antioxidant properties (Münzel and Gori, 2009).
Evidence is emerging in support of improved NO bioavail-
ability as a result of exercise training due to its enhanced
synthesis and to a reduction in its oxidative stress-mediated
destruction. Molecular targets sensitive to the effects of exercise
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FIGURE 3 | Interrelation between nitric oxide and mitochondria in
hepatocytes in metabolic syndrome. The enhanced activities of mtNOS
and iNOS in hepatocytes during insulin resistance promote peroxynitrite
production and cytochrome c release, which are associated with the
peroxidation of mitochondrial lipids and apoptosis. Reduced SIRT3 activity
contributes to mitochondrial dysfunction, which in turn promotes oxidative
stress and chronic inflammation in MS. Taken together, the reviewed studies
suggest that NO and the different NOS isoforms play an important role in
critical pathological states such as endothelial dysfunction and
peroxynitrite-induced cytotoxicity.
training include eNOS and the antioxidant enzyme superox-
ide dismutase. However, many fundamental details of the cel-
lular and molecular mechanisms linking exercise to alterations
in molecular and functional endothelial phenotypes remain to
be discovered (Rush et al., 2005). Thus, the ideal approach to
antioxidant therapy requires the stimulation of NO produc-
tion and the simultaneous inhibition of vascular superoxide
production.
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Targeting NOS uncoupling to reduce oxidative stress is also
possible in humans through the supplementation of the NOS
cofactor tetrahydrobiopterin (BH4) or of its precursor sepi-
apterin. BH4 has been shown to improve endothelial dysfunc-
tion in smokers, diabetic subjects (Heitzer et al., 2000) and
in patients with hypertension, hypercholesterolemia or coro-
nary artery disease (Schulz et al., 2008). Folate, which has mild
antioxidant properties, can reverse NOS uncoupling, possibly via
BH4-dependent mechanisms (Verhaar et al., 2002). Despite these
pre-clinical data, the effects of BH4 and related molecules on car-
diovascular morbidity and mortality remain unknown, although
the possibility of an improved cardiovascular prognosis due to
folate supplementation has been definitively ruled out by several
randomized controlled trials (Bazzano et al., 2006).
Instead of preventing NO degradation through reducing
oxidative stress, it may be possible to provide exogenous NO via
administering NO-donating substances, such as organic nitrates.
However, research has shown that these mediators cause endothe-
lial dysfunction and increase oxidative stress through at least
three different mechanisms, including uncoupling of the ETC,
activation of ROS-producing enzymes (including NOS uncou-
pling), and the direct reaction of nitrate-derived NOwith vascular
superoxide to form ONOO2 (Münzel et al., 2005). In turn, these
mechanisms accelerate, rather than inhibit, oxidative stress.
Recent evidence has suggested that coenzyme Q10 supplemen-
tation may be useful to treat obesity, oxidative stress and the
inflammatory process inMS patients because Co–Q10 is an essen-
tial component of the ETC. The anti-inflammatory response and
lipid-metabolizing effects of coenzymeQ10 are likely mediated by
transcriptional regulation of inflammation and lipid metabolism
(Alam and Rahman, 2014). Curcumin also represents a potential
antioxidant and anti-inflammatory agent. Studies have demon-
strated that curcumin treatment increases oxygen consumption
and significantly decreases lipid and protein oxidation levels in
liver mitochondria isolated from high-fat diet-induced obese
mice compared with untreated obese mice (Martínez-Morúa
et al., 2013). Furthermore, curcumin treatment does not cause
body weight gain or affect mitochondrial NO synthesis. These
findings suggest that obesity induces oxidative stress and mito-
chondrial dysfunction, whereas curcumin may confer protection
against these effects.
Ecdysterone treatment normalizes the levels of stable NO
metabolites in addition to the activities of superoxide, iNOS and
nNOS in mitochondria in the heart of rats with streptozotocin-
induced diabetes (Korkach et al., 2007). These results suggest that
ecdysterone treatment attenuates diabetes-induced mitochon-
drial alterations and protects against oxidative and nitrosative
stresses. A study of insulin-resistant male Zucker obese rats by
Aroor et al. has shown that NADPH oxidase inhibitors (apoc-
ynin and VAS2870) and BH4 fail to modify bradykinin-induced
vasodilatation. This group has shown that superoxide generation
is elevated in vessels of insulin-resistant, morbidly obese subjects
and reduced by the mitochondrial-targeted superoxide dismu-
tase mimetic mito-TEMPO (El Assar et al., 2013). Vasodilatation
has been shown to improve in insulin-resistant morbidly obese
arteries as a result of the activity of the superoxide scavengers,
superoxide dismutase and mito-TEMPO (Aroor et al., 2013).
The blockade of TNF-α with infliximab, but not the inhibition
of iNOS or cyclooxygenase, improves endothelial relaxation and
decreases superoxide formation.
Endoplasmic reticulum stress has been implicated in the mito-
chondrial dysfunction-induced apoptosis of pancreatic beta cells.
Furthermore, mitochondrial dysfunction increases the expression
of the iNOS gene and the production of NO, but NO production
is inhibited by compound C or by the dominant-negative mutant
form of AMP-activated protein kinase (AMPK) K45R (Shen,
2010). Moreover, treatment with 1400W, an inhibitor of iNOS,
prevents endoplasmic reticulum stress and apoptosis induced
by mitochondrial dysfunction (Shen, 2010). Interestingly, the
NO donor S-nitroso N-acetylpenicillamine, the nonspecific NOS
inhibitor NG-nitro-L-arginine methyl ester, and the specific
nNOS inhibitor 1-(2-trifluoromethylphenyl) imidazole signifi-
cantly reduce creatine kinase leakage, cell necrosis, and apop-
tosis in diabetic myocardium (Barua et al., 2011). These results
demonstrate that both the provision of exogenous NO and
the suppression of endogenous NO production result in the
potent protection of diabetic human myocardium, overcoming
the unresponsiveness of these tissues to cardioprotective thera-
pies. The treatment of cells with the NG-nitro-L-arginine methyl
ester (1mmol/l) has been shown to significantly diminish the
TNF-α-mediated sustained downregulation of UCP-2 expression,
whereas treatment with the NO donor S-nitroso-L-glutathione
(1mmol/l) mimics the effect of TNF-α on UCP-2 expression
(Merial et al., 2000).
The modulation of NO-mediated pathways through dietary
supplementation with L-arginine or its precursor L-citrullinemay
represent an effective and practical strategy to prevent and treat
MS, including obesity, T2DM, and dyslipidemia, in mammals
such as humans (Jobgen et al., 2006). Clinical research eval-
uating the effects of arginine and citrulline in mitochondrial
diseases has been limited to uncontrolled, open-label studies,
which have demonstrated that administering arginine to subjects
with mitochondrial encephalomyopathy, lactic acidosis or stroke-
like episodes (MELAS) syndrome results in improvement of the
clinical symptoms associated with the stroke-like episodes and
decreased frequency and severity of these episodes (El-Hattab
et al., 2012).
Pathways that regulate mitochondrial biogenesis have recently
emerged as potential therapeutic targets for the amelioration of
the endothelial and vascular dysfunction observed in metabolic
diseases (Schulz et al., 2008). Shen et al. have suggested that
lipoamide is a potent stimulator of mitochondrial biogene-
sis in adipocytes and may have potential therapeutic appli-
cations in obesity and T2DM (Shen et al., 2010). Lipoamide
dose-dependently stimulates the expression of eNOS and the
formation of cGMP. In addition, knockdown of eNOS using
siRNA prevents lipoamide-induced mitochondrial biogenesis,
which is also blocked by the soluble guanylate cyclase inhibitor
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one and by the protein
kinase G inhibitor KT5823. Thus, the stimulation of mitochon-
drial biogenesis by lipoamide involves signaling via the eNOS-
cGMP-PKG pathway.
Enhanced NO production is known to activate SIRT1, which
is a histone deacetylase that regulates PGC-1α, a regulator of
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mitochondrial biogenesis and a coactivator of transcription fac-
tors that impacts energy homeostasis. Tadalafil-treated diabetic
mice exhibit significantly improved left ventricular function
that is associated with increased cardiac SIRT1 activity (Koka
et al., 2014). Tadalafil also enhances plasma NO oxidation levels,
myocardial SIRT1, PGC-1α expression, and the phosphorylation
of eNOS, Akt, and AMPK in diabetic hearts. Oxidative phospho-
rylation of the complex I substrate glutamate is decreased by 50%
in diabetic hearts compared with non-diabetic controls. Tadalafil
protects oxidative phosphorylation and improves glutamate state
3 respiration rates. Additionally, the increase in ROS produc-
tion from complex I is significantly decreased by treatment with
tadalafil (Koka et al., 2014).
Studies of resveratrol treatment in primary human coronary
arterial endothelial cells have shown that resveratrol induces
mitochondrial biogenesis in these cells. The formation of new
mitochondria is associated with activation of SIRT1, upregulation
of eNOS, and induction of specific mitochondrial biogenesis fac-
tors (Schulz et al., 2008). It has also been shown that resveratrol
treatment inducesmitochondrial biogenesis in the aorta in T2DM
mice (Schulz et al., 2008).
The insulin-sensitizing drug pioglitazone is a ligand of PPARγ
that ameliorates the basic problem of insulin resistance and is
therefore considered to reduce the risk of cardiovascular disease
in patients with T2DM (Yki-Järvinen, 2004). Pioglitazone reduces
myocardial infarct size via the activation of the PPARγ, phospho-
inositide 3-kinase, Akt, and eNOS pathways but not via opening
of the mitochondrial K(ATP) channels. The use of this drug may
be a novel strategy for the treatment of T2DM with coronary
artery disease.
Thus, a deeper understanding of the role of NO and NOS iso-
forms inmitochondrial pathology is necessary for the study ofMS
pathogenesis as well as its complications and clinical applications.
CONCLUSIONS
Themain components of MS, particularly visceral obesity, insulin
resistance, and T2DM, are associated with changes in mitochon-
drial metabolism in different tissues. Mitochondrial dysfunction
may accelerate the progression of insulin resistance and subse-
quent organ dysfunction and has different interconnections with
eNOS, iNOS, nNOS andmtNOS. Themainmechanisms involved
in MS development include augmented generation of mitochon-
drial superoxide that is formed with the participation of NO and
disruptions in mitochondrial respiration and biogenesis that lead
to apoptosis and other consequences. In addition, alterations in
mitochondrial activity that occur in MS may include acquired
or inherited reductions in the mitochondrial oxidative phospho-
rylation capacity, submaximal ADP-stimulated oxidative phos-
phorylation and plasticity of mitochondria and/or reductions in
mitochondrial contents in insulin-sensitive tissues.
Currently, mitochondria remain an attractive target for the
prevention and treatment of metabolic disorders. Therapy based
on the inhibition of iNOS, on the prevention of eNOS uncoupling
and on other effects on the components of the NO pathway may
help to protect against mitochondrial dysfunction associated with
metabolic disorders. Despite great advances in this area, questions
remain about the relationships between mitochondrial function
and the NOSs in various tissues, such as skeletal muscle, liver,
heart and adipose tissues, particularly with regard to the effects
of therapeutic strategies that affect mitochondrial function and
insulin sensitivity.
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